ArticleFrontiers in pharmacology2025
Dynamic relationship between gut microbiota and post-necrotizing pancreatitis: insights from a multi-stage 16S rRNA sequencing study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is a common digestive disorder, with necrotizing pancreatitis (NP) occurring in 20% of cases. Long-term complications can include pancreatic exocrine and endocrine insufficiency, with gut microbiota (GM) playing a significant role in pancreatic diseases. Although previous studies have established a connection between gut microbiota dysbiosis and the onset of necrotizing pancreatitis, the composition of GM in patients who have experienced post-NP post-necrotizing pancreatitis remains largely unexamined. Methods: We conducted a single-center, prospective, long-term follow-up study of 88 participants, including 68 NP patients and 20 healthy controls. NP patients were divided into NP (onset-NP) and PNP groups based on disease progression. Gut microbial diversity and composition were assessed using 16S rRNA sequencing, followed by bioinformatic analyses such as Alpha and Beta diversity metrics, linear discriminant analysis effect size (LEfSe), and functional pathway predictions. Clinical data were correlated with GM profiles to evaluate associations. Results: 29.5% and 19.1% of NP patients progressed to pancreatic endocrine and exocrine insufficiency, respectively. Alpha and Beta diversity analyses revealed significantly lower microbial diversity in NP and PNP groups. Dysbiosis was characterized by a reduction in beneficial bacteria such as Conclusion: Our findings highlight distinct GM profiles in NP and PNP patients compared to healthy controls, with partial recovery of beneficial flora in PNP patients. The study underscores the role of GM dysbiosis in NP progression and long-term outcomes, offering insights into potential therapeutic targets and strategies to improve patient management and quality of life. Future studies should explore multicenter validations and the mechanisms linking GM alterations to clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.